You are here

Jesse Boehm

Boehm JS et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15;129(6):1065-79.

Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 5;462(7269):108-12.

Johannessen CM, Boehm JS, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16;468(7326):968-72.

Cheung HW, Cowley GS, Weir BA, Boehm JS, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. PNAS. 2011 Jul;108(30):1272-7. DOI:10.1073/pnas.1109363108

Lohr JG, et al. Whole-genome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology. [Published online ahead of print on April 20, 2014.] DOI:10.1038/nbt.2892

Jesse Boehm, Ph.D.

Jesse Boehm is the assistant director of the Broad’s Cancer Program and a Merkin Institute Research Fellow. In these roles, he both leads a research team and works closely with Cancer Program director Todd Golub on the scientific planning and strategic execution of program projects, collaborations and activities.

Boehm’s lab is focused on developing powerful methods and tools to accelerate the translation of cancer genomics into cancer therapeutics. Active projects in the lab include developing pipelines for personalized testing of tumor vulnerabilities as part of the Cancer Cell Line Factory, assessing the tumorigenic potential of thousands of new cancer mutations as part of the Target Accelerator, and developing systematic experimental and computational approaches to validate biomarker-dependency relationships as part of Project Achilles.

Previously, Boehm worked for three and a half years as a research scientist in the Broad Cancer Program. In this role he managed several large, collaborative research efforts that spanned multiple platforms, programs and initiatives at the Broad Institute and Dana-Farber Cancer Institute. These included the generation of functional genomics tools for the community as well as the deployment of these tools in systematic, high-throughput experiments to determine the function of elements in the cancer genome.

Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the laboratory of William Hahn at the Dana-Farber Cancer Institute, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous.

April 2014